Diagnosis of non-effusive feline infectious peritonitis by reverse transcriptase quantitative PCR from mesenteric lymph node fine-needle aspirates by Dunbar, Dawn et al.
 
 
 
 
 
Dunbar, D. et al. (2018) Diagnosis of non-effusive feline infectious 
peritonitis by reverse transcriptase quantitative PCR from mesenteric lymph 
node fine-needle aspirates. Journal of Feline Medicine and 
Surgery, (doi:10.1177/1098612X18809165) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
http://eprints.gla.ac.uk/173985/  
                    
 
 
 
 
 
 
Deposited on: 17 January 2019 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk  
 
    1
 
Diagnosis of non-effusive feline infectious peritonitis by reverse 
transcriptase quantitative polymerase chain reaction from mesenteric 
lymph node fine-needle aspirates  
Dawn Dunbar1, Wendy Kwok3, Elizabeth Graham1, Andy Armitage2, Richard Irvine1, 
Pamela Johnston1, Michael McDonald1, Dorothy Montgomery, Lesley Nicolson1, Elise 
Robertson4, William Weir1, Diane D. Addie1* 
 
1 Veterinary Diagnostic Services, School of Veterinary Medicine, College of Medical, 
Veterinary and Life Sciences, University of Glasgow, Bearsden Road, Glasgow, 
G61 1QH 
2 Greenside Veterinary Practice Ltd, Greenside Farm, St Boswells, TD6 0AJ 
3 Department of Infectious Diseases and Public Health, College of Veterinary Medicine 
and Life Sciences, City University of Hong Kong  
4 Feline Vet Ltd, New Priory Veterinary Surgery, Brighton, East Sussex, BN34QN, UK  
 
 
    2
 
* Corresponding author: Diane D. Addie, PhD, BVMS, MRCVS  
Veterinary Diagnostic Services, School of Veterinary Medicine, College of Medical, 
Veterinary and Life Sciences, University of Glasgow, Bearsden, Glasgow, G61 1QH, 
UK 
Tel: +33 (0) 559 286253 
Email: draddie@catvirus.com 
Keywords: feline infectious peritonitis, coronavirus, polymerase chain reaction, RT-
PCR, mesenteric lymph node, fine-needle aspirate, non-effusive FIP, diagnosis, biopsy 
 
 
    3 
Abstract 1 
Objectives: The aim of this study was to evaluate a feline coronavirus (FCoV) 2 
reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) on fine-3 
needle aspirates (FNA) from mesenteric lymph nodes (MLN) collected in sterile 4 
saline for the purpose of diagnosing non-effusive feline infectious peritonitis (FIP) in 5 
cats. 6 
Methods: First, the ability of the assay to detect viral RNA in MLN FNA 7 
preparations compared to MLN biopsy preparations was assessed in matched samples 8 
from eight cats. Secondly, a panel of MLN FNA samples was collected from a series 9 
of cats representing non-effusive FIP cases (n = 20), FCoV seropositive individuals 10 
(n = 8) and FCoV seronegative individuals (n = 18). Disease status of animals was 11 
determined using a combination of gross pathology, histopathology and/or ‘FIP 12 
profile’ consisting of serology, clinical pathology and clinical signs. 13 
Results: Viral RNA was detected in 18 of 20 non-effusive FIP cases; it was not 14 
detected in two cases that presented with neurological FIP. Samples from 18 15 
seronegative non-FIP control cats and seven of eight samples from seropositive non-16 
FIP control cats contained no detectable viral RNA. Thus, as a method for diagnosing 17 
non-effusive FIP, MLN FNA RT-qPCR had an overall sensitivity of 90.0 % and 18 
specificity of 96.1 %. 19 
Conclusions and relevance: In cases with a high index of suspicion of disease, RT-20 
qPCR targeting FCoV in MLN FNA can provide important information to support the 21 
ante-mortem diagnosis of non-effusive FIP. Importantly, viral RNA can be reliably 22 
detected in MLN FNA samples in saline submitted via the national mail service. 23 
When applied in combination with biochemistry, haematology and serological tests in 24 
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cases with a high index of suspicion of disease, the results of this assay may be used 25 
to support a diagnosis of non-effusive FIP. 26 
27 
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INTRODUCTION 28 
Feline coronavirus (FCoV) is an alpha-coronavirus that is ubiquitous among 29 
populations of felidae. FCoV and other viruses within this family are associated with 30 
enteric disease, such as ferret coronavirus, canine coronavirus and transmissible 31 
gastroenteritis virus of pigs1. In addition to its primarily enteric pathogenesis, FCoV is 32 
associated with a progressive disease named feline infectious peritonitis (FIP)2. In the 33 
majority of cases, FCoV infection is not accompanied by overt clinical signs. A 34 
proportion of cats exposed to the virus exhibit signs of mild enteric disease, usually 35 
manifesting as transient diarrhoea, sometimes with vomiting3. In around 5 % of cases4 36 
the virus elicits an aberrant immune response in the host resulting in an almost 37 
invariably lethal pyogranulomatous perivasculitis, a consequence of extravasation of 38 
FCoV-infected monocytes5. FIP is considered to consist of a spectrum of 39 
presentations, with an effusive form at one end and a non-effusive form at the other6. 40 
In recent years, great strides have been made in the diagnosis of effusive FIP. 41 
Collection of effusion samples from the body cavities is a minimally invasive 42 
veterinary intervention. Recent studies have shown that the detection of FCoV by RT-43 
qPCR, using template RNA from the effusion is highly supportive of a diagnosis of 44 
effusive FIP7-10, although two recent studies did find low amounts of FCoV RNA in 45 
effusions of one of 29, and one of 47 cats in their control groups of cats without FIP7, 46 
11. However, as a minimally invasive sampling technique has not been described for 47 
non-effusive FIP, confirmation is often achieved only at the time of post-mortem. A 48 
major difficulty in the diagnosis of FIP is the vast and variable range of clinical signs 49 
associated with the disease. Although haematological, biochemical and serological 50 
parameters may be measured to provide an index of suspicion of FIP; these cannot be 51 
used to confirm a diagnosis. 52 
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Cats are frequently subjected to invasive biopsy procedures, which often do not result 53 
in a conclusive diagnosis. Kipar et al.12 described one manifestation of non-effusive 54 
FIP primarily presenting as enlargement of the mesenteric lymph nodes (MLN), 55 
similar to a manifestation of coronavirus-induced pyogranulomatosis reported in the 56 
ferret13, and frequently mistaken for tumours in both species12, 14. In one study, 57 
pyogranulomatous lesions were found in the MLNs in eight (33%) of 24 cats with 58 
FIP15 while in another, mesenteric lymphadenopathy was noted by ultrasound in nine 59 
of 16 cats with FIP16. It should be appreciated that other conditions, such as 60 
toxoplasmosis, can also present with enlarged mesenteric lymph nodes17. 61 
Histopathological identification of FIP lesions in biopsies is currently the only method 62 
to confirm a diagnosis of non-effusive FIP. However, histopathology of the lymph 63 
node in FIP can reveal non-specific pyogranulomatous inflammation, which has many 64 
possible causes. In such cases, immunohistochemistry (IHC) to detect FCoV-specific 65 
proteins may be performed. The reliability of IHC depends on the specificity of the 66 
assay. A poorly designed assay, such as one with no negative control antibody run for 67 
every section of tissue on which the anti-FCoV antibody is run, will fail to identify 68 
non-specific adherence of antibodies to some feline tissues, causing false positive 69 
results (unpublished observation). IHC can also lack sensitivity, as it depends on the 70 
surgeon submitting an area of the organ in which virus-infected cells were present. In 71 
non-effusive FIP there may be few lesions and in order to obtain an accurate biopsy 72 
an exploratory laparotomy is usually required. Laparotomy for the collection of 73 
biopsy material is an invasive, potentially stressful and risk-associated intervention, 74 
which may adversely affect an already sick cat where FIP is suspected. It has been 75 
shown that cats with FIP often have a history of stress18, 19 although it is unknown 76 
whether experiencing further stress after FIP has developed affects the outcome. 77 
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Moreover, immunosuppressive doses of corticosteroids, routinely used for FIP 78 
treatment, are contra-indicated in cats that have undergone recent surgery, as they 79 
hamper the healing process. In contrast, ultrasound-guided collection of fine-needle 80 
aspirate material is a far less invasive procedure. 81 
The detection of viral ribonucleic acid (RNA) in faeces or blood or the detection of 82 
anti-FCoV antibodies in the blood is not diagnostic of FIP. Combinations of all three 83 
findings may be present in FCoV-infected cats which are healthy, or which are sick 84 
due to non-FIP diseases6. As a considerable proportion of the feline population may 85 
be positive for FCoV antibodies, up to 26% in the UK20, a major challenge for the 86 
clinician is the diagnosis of FIP in the FCoV seropositive cat where the presence of 87 
antibodies may either be incidental or may be associated with FIP. The predictive 88 
value of a negative FCoV antibody test for ruling out FIP has been calculated as 89 
97%21 and therefore a seronegative result usually excludes FIP provided that a 90 
sufficiently low initial serum dilution is used, such as 1:2022. 91 
Previous studies have shown results consistent with a diagnosis of non-effusive FIP 92 
can be observed through microscopic examination of smear preparations from FNAs 93 
or Tru-cut biopsies of the liver and/or kidney23. However, in many cases such samples 94 
provide inadequate material for analysis due to the destruction of cellular 95 
morphology, thus reducing test sensitivity23. We hypothesised that the problem of 96 
cellular damage could be avoided by using reverse-transcriptase quantitative 97 
polymerase chain reaction (RT-qPCR) to detect FCoV in FNA samples derived from 98 
MLN. Such a technique has the potential to be a minimally invasive diagnostic test 99 
for non-effusive FIP. The aim of the present study, therefore, was to evaluate the 100 
diagnostic potential of MLN FNAs combined with FCoV RT-qPCR. As an initial 101 
step, the sensitivity of this method was compared to RT-qPCR of MLN biopsies 102 
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(MLNB). In a prospective study, the specificity of  MLN FNA FCoV RT-qPCR was 103 
then analysed using samples from groups of cats that were (a) FCoV seronegative, (b) 104 
seropositive but without signs indicative of FIP (or had confirmation of other 105 
diseases/causes of death) and (c) FIP cases. MLN FNA samples submitted to the 106 
Veterinary Diagnostic Service at the University of Glasgow were also evaluated to 107 
determine if non-preserved (i.e. saline) samples submitted from field clinics would be 108 
suitable, thereby assessing if transit to the laboratory adversely affected test 109 
sensitivity. A full assessment of the sensitivity, specificity and diagnostic accuracy of 110 
the method was performed. 111 
MATERIALS AND METHODS 112 
Sources of clinical samples 113 
Samples from eight FIP cases were used for an initial study (Group T). The main 114 
study then included a group of twenty cats with non-effusive FIP (Group D), a control 115 
group of eight seropositive cats without FIP (Group P) and a second control group of 116 
eighteen seronegative cats (Group N) also without FIP; details of the source of 117 
samples for these three groups are provided in Table 1. A proportion of these samples  118 
(n = 25) was collected from cats in the post-mortem room at the School of Veterinary 119 
Medicine, University of Glasgow that had been submitted for post mortem from 120 
veterinary practices throughout the UK. The remainder of samples came directly from 121 
referring veterinary surgeons across the UK including MLN FNAs collected in vivo 122 
and submitted in a small amount of sterile saline in a plain tube (n = 13), MLNB 123 
material collected in vivo (n = 1) and MLNB collected post mortem (n = 7) by 124 
referring veterinary surgeon and submitted to the laboratory by first class post. 125 
Samples received in the laboratory were stored at 4 ºC until processed. The time from 126 
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sample collection to processing ranged from 24 hours to 7 days, with most samples 127 
being processed between 48 and 72 hours post-collection. 128 
Preparation of samples 129 
Collection of mesenteric lymph node biopsy material (MLNB) 130 
MLN biopsies were collected post mortem by the University of Glasgow post-mortem 131 
room pathologist (supplementary material 1) or in vivo by the submitting veterinary 132 
surgeon during exploratory laparotomy or post mortem. Samples were placed in 133 
sufficient sterile saline to cover the biopsy material for transit to the laboratory. 134 
Mesenteric lymph node fine-needle aspirates (MLN FNAs) 135 
MLN FNA samples were collected either in vivo at participating veterinary practices 136 
or in situ at the University of Glasgow during post-mortem examination or extra 137 
corpus in the laboratory from excised lymph nodes. In vivo MLN FNA samples 138 
collected by ultrasound guidance or at exploratory laparotomy were expelled into 139 
0.2 - 0.5 mL sterile saline in plain tubes and then mailed to the laboratory by first-140 
class post, without refrigeration. Post mortem samples were collected in situ using a 141 
21-gauge needle and a 2 mLsyringe, MLNB was also collected to be stored as 142 
backup. Extra corpus FNAs were performed on either MLNB or whole MLN 143 
collected ante mortem (n = 1) or during post-mortem examination (n = 7).  Paired 144 
FNA samples were prepared using a 21-gauge needle and a 2 mL syringe; one was 145 
expelled into 0.5 mL sterile saline and the other expelled into 0.5 mL RNAlater 146 
(Ambion, Huntingdon, UK) to inactivate RNAses and maintain the integrity of RNA 147 
therein during long-term storage. FNAs collected into RNAlater and any remaining 148 
MLNB (approximately 0.5 cm cubed/ 0.5 mL RNAlater) were stored in our biobank. 149 
FIP diagnosis 150 
    10 
Diagnosis of FIP was confirmed by histopathology where suitable sample material 151 
was available. Sufficient blood and tissue samples for virology, clinical pathology and 152 
histopathology had been collected in these cases to acquire a diagnosis. Tissue 153 
samples for histopathology were collected in 10% formal saline, including MLN and 154 
one or more of the following: kidney, liver, lung, spleen, omentum and any others 155 
deemed relevant for diagnosis. Where histopathology was unavailable or 156 
inconclusive, FIP diagnosis was based on the laboratory testing steps of the European 157 
Advisory Board of Cat Diseases (ABCD) FIP diagnosis algorithm6 as performed 158 
under the VDS laboratory ‘non-effusive FIP profile’. This commercial test profile 159 
comprises the following suite of blood tests: FCoV antibody titre, alpha-1 acid 160 
glycoprotein (AGP) measurement24, 25, albumin:globulin ratio, haematocrit and 161 
lymphocyte count. In group D (non-effusive cases, n = 20), 10 cases were confirmed 162 
by histopathology/IHC, one by gross pathology and the remainder being highly 163 
suspected of FIP on the basis of FIP profile. In the control groups, FIP was ruled out 164 
by a combination of histopathology and gross post-mortem examination in the 165 
seropositive group (P) in 7 of 8 cats and in the seronegative group (N) in 17 of 18 166 
cats. A negative FIP profile was used to rule out FIP in a single case in each of the 167 
control groups. (Table 1.) 168 
RNA extraction 169 
RNA extraction from both MLNB and MLN FNA samples was performed using the 170 
RNAqueous 4-PCR extraction kit (Ambion, Huntingdon, UK). All materials form part 171 
of the RNAqueous 4-PCR kit unless otherwise stated. All equipment was wiped with 172 
RNAse ZAP (Ambion). Tubes and pipette tips (Sarstedt, Germany) were RNAse and 173 
DNAse free. MLNB samples were cut into portions not larger than 0.075 g, added to 174 
a gentleMACS M tube (Miltenyi Biotech, Bergisch Gladbach, Germany) with 700 µL 175 
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lysis buffer and homogenised by a gentleMACS Dissociator (Miltenyi). The M tube 176 
was centrifuged at 1,000 rpm at 4ºC, for 10 minutes to ensure all material was lysed 177 
and this step was repeated if required. RNAse and DNAse free phosphate buffered 178 
saline (PBS) solution (Sigma) at 4ºC was added to the MLN FNA sample in saline 179 
and centrifuged at 1,000 rpm at 4ºC. The resulting supernatant was discarded and the 180 
pellet resuspended in 250 µL lysis buffer. Lysed MLNB and MLN FNA samples were 181 
kept on ice at all times. The extractions were performed as per the manufacturer’s 182 
instructions, followed by DNAse treatments to remove contaminating DNA. The 183 
RNA extract was transferred to a 1.5 mL tube (Sarstedt, Germany) and stored at 184 
minus 80ºC. The RNA extract underwent quantification and quality analysis using a 185 
Nanodrop 2000 (Thermo Fisher Scientific, Wilmington, DE, USA). 186 
Reverse-transcriptase real-time PCR 187 
The quantitative FCoV RT-qPCR assay was modified from the method of Gut et al.26, 188 
based on the conserved 3' UTR region of the FCoV genome. This assay is capable of 189 
detecting both type I and type II FCoV. RT-qPCR was performed using the 190 
Superscript ® III Platinum ® One Step RT-PCR System (Invitrogen, Carlsbad, CA, 191 
USA). Unless otherwise stated, reagents were sourced from Invitrogen (Carlsbad, CA, 192 
USA). Primer and probe sequences are detailed in Table 2. Each reaction consisted of 193 
nuclease free PCR-grade water (Hyclone, GE Healthcare Life Sciences, UK/Qiagen, 194 
UK), reaction mix containing dNTPs, 500 nM FCoV forward primer (Eurofins MWG 195 
Operon, Ebersberg, Germany), 1 µM FCoV reverse primer (Eurofins MWG Operon), 196 
200 nM FCoV probe (Eurofins MWG Operon), 25 mM ROX passive reference dye 197 
and Superscript Platinum III. 17 µL of master mix was loaded into each well of a 96 198 
well plate (Applied Biosystems, Foster City, CA, USA) and 3 µL of RNA extract or 199 
assay control was added as required. The plate was then centrifuged briefly to 200 
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eliminate air bubbles before RT-qPCR was performed using the 7500 RT-PCR 201 
System (Applied Biosystems). A reverse-transcriptase step was performed at 48ºC for 202 
30 minutes, followed by a denaturing step at 95ºC for 2 minutes. Thereafter, 40 cycles 203 
consisting of 95ºC for 15 seconds and 60ºC for one minute were performed. Samples 204 
were run in duplicate; no samples were found to produce conflicting results. Samples 205 
in which an amplicon was not detected by the 40th cycle were deemed to be negative. 206 
The Ct value for each reaction was recorded, with a lower Ct value, resulting from 207 
greater template RNA in the reaction mixture. GAPDH RT-qPCR was also performed 208 
on each sample; this was particularly important for FCoV RNA negative samples to 209 
demonstrate that there was sufficient RNA in each reaction. The protocol was the 210 
same as that of the FCoV RT-qPCR described above, with the primers and probe 211 
substituted for GAPDH specific primers and probe (see Table 2). 212 
FCoV indirect immunofluorescent antibody test 213 
The FCoV indirect immunofluorescent antibody test (IFA) was performed as 214 
previously described27. 215 
Statistical analysis 216 
Fisher’s Exact test (two-tailed) and the Pearson correlation co-efficient (r) were 217 
calculated using the core “stats” package in R28. Scatter plots were generated using 218 
“ggplot2” in R28, 29. Inter-rater agreement was determined using a 2x2 contingency 219 
table and the kappa statistic (κ) with 95 % confidence intervals calculated using the 220 
“fmsb” package in R28, 30. 221 
RESULTS 222 
Viability of MLN FNAs for FCoV qRT-PCR assays  223 
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A panel of matched MLN FNAs and MLNBs was assembled from a total of eight cats 224 
with a confirmed diagnosis of FIP (T01-T08). The quantity of RNA recovered from 225 
FNA preparations varied between 3 and 199 ng/µl, while that recovered from the 226 
MLNB preparations varied between 178 and 1,855 ng/µl (supplementary material 1). 227 
On average, a 35-fold lower concentration of RNA was recovered by FNA than by 228 
MLNB preparation, although this varied widely. 229 
RT-qPCR was performed to evaluate the presence of host (GAPDH) and viral RNA in 230 
both the FNA and MLNB preparations. FCoV RNA was detected in each FNA and 231 
MLNB preparation, as was the presence of host-encoded RNA. Overall, slightly 232 
higher Ct values were noted for both host and viral genes for the MLN FNA 233 
reactions, indicating a lower level of template nucleic acid. MLN FNA FCoV Ct 234 
values ranged from 19.4 to 36.1 whereas for MLNB FCoV the range was 18.0 to 28.1, 235 
with lower MLNB FCoV Ct values recorded in each of the paired samples. The 236 
relationship of FCoV Ct value between sample types is illustrated in Figure 1. For the 237 
MLN FNA preparations, a strong negative correlation existed between the GAPDH 238 
Ct value and the concentration of total RNA (r = -0.87, P < 0.01), as expected. 239 
However, only a moderate correlation, which was not statistically significant, existed 240 
between the FCoV Ct value and total RNA concentration (r = -0.61, P = 0.11), and 241 
therefore it could not be concluded that the level of template viral RNA (i.e. viral 242 
load) was fully dependent on the concentration of total RNA, the majority of which is 243 
host-encoded. 244 
Viability of RNA in MLN FNAs collected in the field 245 
As GAPDH RT-qPCR Ct values were shown to strongly correlate with RNA 246 
concentration and are dependent on viable host RNA, these values were used as an 247 
index for RNA sample quality, in terms of both quantity and intactness. GAPDH Ct 248 
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values of 32 MLN FNA samples prepared / collected at the University were compared 249 
to twelve samples submitted by mail from external veterinary practices, in order to 250 
check for potential RNA deterioration while in transit (supplementary material 2). 251 
The median in-house Ct value was 25.8 while that from external samples was only 252 
marginally higher at 28.4 and so it can be concluded that a similarly high level of 253 
RNA was found in fresh samples and in those that had been sent by post. 254 
Sensitivity and specificity of the MLN FNA FCoV RT-qPCR assay 255 
FCoV was detected by RT-qPCR in 18 of the 20 cats with non-effusive FIP (Group 256 
D). Two extracts contained no detectable FCoV RNA, although both contained ample 257 
reference gene RNA, and therefore the test sensitivity was 90 %. Interestingly, these 258 
samples represented the only neurological cases of FIP in this group and this 259 
association was found to be statistically significant (P = 0.0053, Fishers Exact Test). 260 
FCoV Ct values varied between 22.7 and 38.2 and these showed a moderate 261 
correlation with GAPDH Ct values (r = 0.72, P < 0.01). This relationship is illustrated 262 
in Figure 2. Of the 26 cats in the study that did not have FIP (control groups P and N), 263 
FCoV was detected in only one cat and thus the overall test specificity was 96.1 %. In 264 
practice, an FCoV seronegative status would tend to rule out a diagnosis of FIP and, 265 
therefore, this assay has particular relevance to the cohort of non-FIP seropositive 266 
cats; the specificity with respect to this group was 87.5 %. The positive sample, with a 267 
Ct value of 23, was from cat P04, which was subsequently diagnosed with 268 
suppurative bronchopneumonia. Sections from kidney, lung, liver and spleen were 269 
analysed by immunohistochemistry but FCoV antigen was not detected in any of the 270 
tissues examined. A 2x2 contingency table was generated to evaluate the performance 271 
of the MLN FNA RT-qPCR assay compared to standard diagnostic tools for FIP. The 272 
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results demonstrated a high inter-rater agreement, which was almost perfect (κ = 0.88; 273 
95 % CI 0.75-1.0). 274 
DISCUSSION 275 
A sensitive, specific and minimally invasive method for supporting or refuting a 276 
diagnosis of non-effusive FIP is currently required. A PCR and sequencing based 277 
method has recently been developed, which targets a mutated form of FCoV7, 31, 32. 278 
Although a positive result may be supportive of FIP, the assay suffers from 279 
unacceptably low sensitivity (6.5 %) when applied to blood samples31 and a recent 280 
study concluded that gene mutation analysis does not substantially improve the ability 281 
to diagnose FIP as compared to detection of FCoV alone32. This leads to the 282 
supposition that an alternative approach, the use of a PCR protocol capable of 283 
detecting the virus in a key anatomical site, i.e. mesenteric lymph node tissue, may 284 
have more diagnostic utility for suspect cases of non-effusive FIP. Laparotomy for the 285 
collection of biopsy material is a potentially stressful and risk-associated intervention. 286 
In contrast, sample collection by ultrasound-guided fine-needle aspirate is a far less 287 
invasive procedure and therefore an opportunity exists to develop a novel assay for 288 
FIP diagnostics using this methodology. While cytology of effusions in FIP is useful 289 
in establishing alternative diagnoses such as neoplasia or bacterial peritonitis, 290 
cytology of enlarged mesenteric lymph node FNA often provide limited clear 291 
diagnostic information, with cytology often described as consistent with reactive 292 
hyperplasia (unpublished observation). Norris et al.  described reactive hyperplasia in 293 
4/5 cases of confirmed FIP where cytology had been performed on MLN FNA and 294 
1/5 cases as pyogranulomatous inflammation33. In all cases, these observations are 295 
non-specific characteristics that are merely suggestive of FIP, and add no solid 296 
support. However, a PCR-based assay offers the potential of improved performance 297 
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and so the present study set out to investigate whether detecting viral RNA in fine-298 
needle aspirates of MLNs could be used to support a diagnosis of FIP. As a first step, 299 
we demonstrated that both host and FCoV RNA can be reliably detected in samples 300 
from MLN FNAs as well as in MLNB. The results of the GAPDH RT-qPCR control 301 
assay confirmed that sufficient quantities of host RNA can be recovered from MLN 302 
FNA samples. Importantly, a very similar level of RNA was recovered from fresh 303 
MLN FNA samples prepared in the laboratory and MLN FNA samples which had 304 
been collected by submitting veterinary surgeons and sent via the postal system, 305 
without any form of preservative. This means that the samples submitted without the 306 
use of nucleic preservatives or refrigeration are suitable for use with this assay. 307 
Enlarged MLNs are frequently observed in FIP cases; in all five FIP cases where 308 
lymph node size was recorded in the clinical history in the present study, it was 309 
described as enlarged. It is from such enlarged MLNs that we would advise taking 310 
FNAs. However, if MLNs are of normal size, even using ultrasound guidance, then 311 
accessibility and stabilisation of the lymph node are likely the most important factors 312 
to allow aspiration of adequate material to test. Other studies suggest sampling from 313 
the kidney, and although this organ may be easier to sample, experimental infections 314 
provide evidence of lower viral load in these tissues34. Our study, focusing on 315 
sampling enlarged MLNs, builds on the work of Kipar et al. who detected FCoV viral 316 
RNA by RT-PCR in the MLN of 13 of 15 (87 %) of cats with FIP35. However, as 317 
FCoV is primarily an enteric pathogen, its presence in lymph nodes draining the 318 
gastrointestinal tract may also be anticipated in FCoV-infected cats without FIP35 . 319 
Thus, the study was designed to address two issues: whether in principle RT-qPCR 320 
could detect the virus in MLN FNA RNA preparations and, if so, whether it could be 321 
a sensitive and specific diagnostic method for FIP investigation. 322 
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Samples representing 25 of 26 (96.1 %) seronegative or seropositive cats without FIP 323 
did not generate a PCR product and thus a diagnosis of FIP was not supported in these 324 
cases. FCoV RNA was detected in only one seropositive kitten, P04, which presented 325 
with diarrhoea, dyspnoea, a pleural effusion and a highly elevated white cell count. 326 
On the basis of histopathology, this cat was subsequently diagnosed with suppurative 327 
bronchopneumonia although no bacteria were recovered from the biopsy material. 328 
While lesions typical of FIP were not detected by histopathology, the possibility that 329 
this cat suffered concurrently from FIP cannot be excluded. This sample demonstrates 330 
that FCoV may be detected in the MLN of a small proportion of cats that do not have 331 
FIP. Notably, this cat had an intermittent history of diarrhoea, which increased in 332 
severity shortly before its death, although it is unknown whether this was FCoV-333 
associated or not. The MLNs are the local draining lymph nodes for the intestinal tract 334 
and it is to be expected that at some point during enteric infection by FCoV there will 335 
be a transient viral presence in those nodes, following transport by macrophages. It 336 
may be hypothesised that, in terms of FIP diagnosis, there is the risk of a false 337 
positive result if the animal is tested in this early period of infection. However, it 338 
should be appreciated that in practice, this diagnostic test should only be applied 339 
when there is a strong index of suspicion of FIP, based on clinical presentation and 340 
other laboratory test parameters. This test is not designed to be a screening assay for 341 
healthy cats and its application would not be indicated in cases of enteric infection 342 
where diarrhoea is the principal clinical sign.  343 
However, there remains the potential risk of detecting FCoV in cats experiencing an 344 
early FCoV infection, but which have nevertheless been tested because of a 345 
concurrent illness, presenting with clinical signs suggestive of FIP. A group of 346 
particular concern would be FCoV carrier cats. These individuals are persistently 347 
infected with FCoV in the gut and continually shed virus in the faeces, however they 348 
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rarely develop FIP36. We can report that MLN biopsy samples from two carrier cats 349 
persistently infected with FCoV, collected during the course of a previous study37, 350 
were found to be FCoV RNA negative (unpublished data). 351 
In most instances, the first step in FIP diagnosis is to perform haematology, 352 
biochemistry and FCoV serology in order to assess the likelihood of the disease. The 353 
MLN FNA assay is likely to be most useful in cases where standard non-invasive 354 
diagnostic tests produce equivocal results or to further support a diagnosis in cases 355 
where FIP is strongly suspected. Eighteen of 20 (90 %) of cases were correctly 356 
classified as having FIP by the MLN FNA assay. Two samples, D12 and D13, had 357 
been diagnosed histopathologically with neurological FIP and tested negative on 358 
FCoV RT-qPCR. This association was found to be statistically significant and was not 359 
a wholly unexpected finding. FIP is commonly sub-divided into effusive and non-360 
effusive forms. On the basis of these results, and those of others18, 38, 39, further 361 
classification of non-effusive cases may be useful with respect to determining 362 
appropriate diagnostic approaches. In the neurological manifestation of FIP, the virus 363 
may have been sequestered in the neural tissues, and thus absent from the MLNs. In 364 
one of these two cases, D13, FCoV was detected by RT-qPCR in the CSF. Similarly, 365 
in cases of suspected FIP-associated uveitis, the virus may be detected in aqueous 366 
humor (unpublished observation). Further data are required in FIP cases with 367 
neurological manifestations of FIP, and it is possible that among cases of this type the 368 
sensitivity of this assay may be limited. Additionally, further studies with larger 369 
numbers of non-FIP, FCoV-seropositive cats are required to more accurately measure 370 
the specificity of MLN FNA FCoV RT-qPCR for this presentation of FIP. 371 
The overall sensitivity of the assay was 90 % (FCoV detected in 18 of 20 FIP cases) 372 
and the specificity was 96.1 % (FCoV not detected in 25 of 26 controls). Very good 373 
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agreement was demonstrated between the MLN FNA assay and the standard 374 
diagnostic tools, with an inter-rater agreement (κ) of 0.88. Thus, overall, the results of 375 
the study suggest that presence of FCoV in the MLN of systemically ill cats is 376 
associated with a diagnosis of FIP. This test, therefore, has value aiding the diagnosis 377 
of FIP in cats with a high index of suspicion of disease. This assay is not proposed as 378 
a standalone method to diagnose FIP and should be used to complement the standard 379 
suite of haematological, biochemical and serological tests currently in use. 380 
CONCLUSIONS 381 
The results of this study are encouraging: FCoV RT-qPCR of FNA of the MLN is a 382 
useful tool to aid diagnosis of non-effusive FIP. This assay can detect FCoV in MLN 383 
FNAs from confirmed FIP cases whilst not detecting FCoV in samples from 384 
seronegative cats and the majority of FCoV seropositive cats without FIP. While 385 
having limited power to identify neurological cases of FIP, the test is highly sensitive 386 
when applied to suspect ‘classic’ systemic FIP cases. As the technique is far less 387 
invasive than traditional biopsy and provides useful diagnostic information, it 388 
represents a useful addition to the suite of current diagnostic methods for FIP. 389 
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Table 1: Mesenteric lymph node fine needle aspirate sample source and classification 514 
Sample 
ref 
FCoV 
antibody 
titre 
Sample 
origin 
MLNB 
collection 
MLN FNA 
collection 
MLN 
size 
Mass(s) 
detecte
d 
(locatio
n) 
Neuro
logica
l signs 
Ocula
r 
signs 
Other 
signs 
† 
 
 
Other Diagnosis 
Lesions 
detected 
on 
histology 
± IHC 
confirmi
ng FIP 
Gross 
post-
morte
m 
lesions 
highly 
sugges
tive of 
FIP 
FIP 
highly 
suspect
ed 
using 
ABCD 
guidelin
es 
Group D - non-effusive FIP cases (n = 20) 
D01 >1:1280 UniPM 
 Post 
mortem, in 
situ 
NR    ✓  
Non-effusive 
FIP ✓   
D02 >1:1280 UniPM 
 Post 
mortem, in 
situ 
NR  ✓  ✓  
Non-effusive 
FIP ✓   
D03 >1:1280 Field 
 Ante-
mortem, in 
situ 
NR     
No clinical 
signs 
(abnormality 
detected on 
routine 
bloods) 
Non-effusive 
FIP 
  ✓ 
D04 >1:1280 UniPM 
 Post 
mortem, in 
situ 
Enla
rged 
   ✓  
Non-effusive 
FIP 
✓   
D05 >1:1280 Field 
Ante 
mortem 
Ante 
mortem, 
extra 
corpus 
NR 
Abdomin
al 
  ✓  
Non-effusive 
FIP 
  ✓ 
D06 >1:1280 Field 
 Ante-
mortem, in 
situ 
Enla
rged 
MLN   ✓  
Non-effusive 
FIP 
  ✓ 
D07 >1:1280 Field 
 Ante-
mortem, in 
situ 
Enla
rged 
MLN and 
Liver 
  ✓  
Non-effusive 
FIP   ✓ 
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D08 >1:1280 Field 
 Ante-
mortem, in 
situ 
NR    ✓  
Non-effusive 
FIP 
  ✓ 
D09 >1:1280 Field 
 Ante 
mortem, in 
situ 
NR 
Abdomin
al 
    
Non-effusive 
FIP 
  ✓ 
D10 1:1280 Field 
Post 
mortem 
Post 
mortem, 
extra 
corpus 
Enla
rged 
   ✓  
Non-effusive 
FIP ✓   
D11 >1:1280 Field 
Post 
mortem 
Post 
mortem, 
extra 
corpus 
NR    ✓  
Non-effusive 
FIP ✓   
D12 >1:1280 UniPM 
 Post 
mortem, in 
situ 
NR  ✓  ✓  
Neurological 
FIP ✓   
D13 1:640 UniPM 
 Post 
mortem, in 
situ 
NR  ✓ ✓ ✓  
Neurological 
FIP 
✓   
D14 >1:1280 Field 
 Ante-
mortem, in 
situ 
NR      
Non-effusive 
FIP 
  ✓ 
D15 >1:1280 Field 
 Ante-
mortem, in 
situ 
NR   ✓   
Non-effusive 
FIP & 
toxoplasmosis 
✓   
D16 >1:1280 Field 
 Ante-
mortem, in 
situ 
Enla
rged 
MLN   ✓  
Non-effusive 
FIP   ✓ 
D17 >1:1280 UniPM 
 Post 
mortem, in 
situ 
NR    ✓  
Non-effusive 
FIP  ✓  
D18 1:320 Field 
 Ante-
mortem, in 
situ 
NR    ✓  
Non-effusive 
FIP ✓   
D19 >1:1280 Field 
Post 
mortem 
Post 
mortem, 
extra 
corpus 
NR     
No clinical 
signs 
(abnormality 
detected on 
Non-effusive 
FIP ✓ ✓  
    28 
routine 
bloods) 
D20 >1:1280 Field 
 Ante-
mortem, in 
situ 
NR MLN   ✓  
Non-effusive 
FIP 
  ✓ 
Group P - FCoV seropositive non-FIP control cases (n = 8) 
P01 1:1280 UniPM 
 Post 
mortem, in 
situ 
Enla
rged 
MLN   ✓  
Toxocara 
infestation ✗   
P02 1:1280 UniPM 
 Post 
mortem, in 
situ 
Enla
rged 
   ✓  NAD ✗   
P03 >1:1280 UniPM 
 Post 
mortem, in 
situ 
Enla
rged 
 ✓  ✓  
Nutritional 
hyperparathyr
oidism leading 
to osteopenia. 
Possible 
osteogenesis 
imperfecta. 
 ✗  
P04 1:1280 Field 
Post 
mortem 
Post 
mortem, 
extra 
corpus 
NR    ✓ 
Respiratory 
signs 
Suppurative 
bronchopneu
monia 
(bacterial 
culture 
negative) 
✗   
P05 1:1280 Field 
 Ante-
mortem, in 
situ 
Enla
rged 
   ✓  
Lymphocytic 
plasmacytic 
enteritis 
✗   
P06 >1:1280 Field 
 Ante-
mortem, in 
situ 
Not 
enlar
ged 
    Healthy 
Survived 12 
months post-
testing 
  ✗ 
P07 1:320 Field 
Post 
mortem 
Post 
mortem, 
extra 
corpus 
Not 
enlar
ged 
    Trauma 
Suspected 
RTA/ trauma  ✗ ✗ 
P08 1:40 Field 
Post 
mortem 
Post 
mortem, 
extra 
corpus 
NR    ✓  
Acute myeloid 
leukaemia and 
secondary 
gastric 
 ✗  
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trichobezoar 
Group N - FCoV seronegative non-FIP control cases (n = 18) 
N01 <1:10 UniPM 
 Post 
mortem, in 
situ Not 
enlar
ged 
 ✓    
Signs of 
inflammatory 
process in 
neural tissues, 
Borna virus 
infection 
suspected 
 ✗  
N02 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR 
Tumour 
ear 
   
Shelter cat, 
teaching case 
NAD  ✗  
N03 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR     
Shelter cat, 
teaching case 
NAD  ✗  
N04 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR     
Shelter cat, 
teaching case 
NAD  ✗  
N05 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR     
Shelter cat, 
teaching case 
NAD  ✗  
N06 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR     
Shelter cat, 
trauma 
NAD  ✗  
N07 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR     
Shelter cat, 
teaching case 
NAD  ✗  
N08 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR     
Shelter cat, 
teaching case 
NAD  ✗  
N09 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR     
Shelter cat, 
teaching case 
Renal failure  ✗  
N10 <1:10 UniPM 
 Post 
mortem, in 
situ 
NR     
Shelter cat, 
spinal 
deformity 
NAD  ✗  
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N11 <1:10 Field 
 Ante-
mortem, in 
situ 
Enla
rged 
   ✓  
Survived 
greater than 4 
months post-
testing 
  ✗ 
N12 <1:10 UniPM 
 Post 
mortem, in 
situ 
Not 
enlar
ged 
    Trauma Head trauma  ✗  
N13 <1:10 UniPM 
 Post 
mortem, in 
situ Not 
enlar
ged 
    
Shelter cat, 
FIV positive 
Chronic 
glomerulonep
hropathy, 
cardiomyopat
hy and 
chronic 
pancreatitis 
 ✗  
N14 <1:10 UniPM 
 Post 
mortem, in 
situ 
Enla
rged 
   ✓  
Foreign body 
in jejunum; 
early 
carcinoma in 
the lung with 
secondary 
pneumonia. 
✗   
N15 <1:10 UniPM 
 Post 
mortem, in 
situ 
Not 
enlar
ged 
    
Respiratory 
signs 
Pneumonia 
and 
concurrent 
bacterial 
infection 
 ✗  
N16 <1:10 UniPM 
 Post 
mortem, in 
situ 
Not 
enlar
ged 
    
Found dead 
after missing 
2 days 
Trauma likely 
due to road 
accident 
✗ ✗  
N17 <1:10 Field 
Post 
mortem 
Post 
mortem, 
extra 
corpus 
NR 
Abdomin
al 
  ✓  NAD ✗   
N18 <1:10 UniPM 
 Post 
mortem, in 
situ 
Not 
enlar
ged 
   ✓  
Intusussceptio
n, string 
foreign body, 
suppurative 
peritonitis. 
✗ ✗  
 515 
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Field: MLNB or MLN FNA collected by referring veterinary surgeon 516 
UniPM: MLN FNA collected by University of Glasgow pathologist 517 
NR: Not recorded 518 
NAD: No abnormality detected 519 
† Non-specific signs including but was not limited to pyrexia, lethargy, inappetence and icterus 520 
✓: clinical sign present / test results support a diagnosis of FIP 521 
✗: test results do not support a diagnosis of FIP 522 
IHC : immunohistochemistry 523 
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Table 2: Primers and probes sequences used in the RT-PCR assay 524 
Target Gene Primer or Probe Sequence (5’  3’) 
FCoV 7b gene* Forward primer GAT TTG ATT TGG CAA TGC TAG ATT T 
Reverse primer AAC AAT CAC TAG ATC CAG ACG TTA GCT 
Probe TCC ATT GTT GGC TCG TCA TAG CGG A 
GAPDH Forward primer GCC GTG GAA TTT GCC GT 
Reverse primer GCC ATC AAT GAC CCC TTC AT 
Probe CTC AAC TAC ATG GTC TAC ATG TTC CAG TAT 
GAT TCCA 
*Designed by Gut et al. (1999)
 
to amplify the FCoV 7b gene  525 
  526 
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Figures 527 
 528 
 529 
Figure 1. Bar chart illustrating the relationship between FCoV RT-qPCR Ct values 530 
from matched mesenteric lymph node biopsy (MLNB) and fine-needle aspirate (FNA) 531 
samples. The Ct values from MLNBs were generally lower than those from MLN 532 
FNAs, indicating higher virus loads in the MLNB pieces than in FNAs. However, three 533 
samples produced MLNB and MLN FNA Ct values which were almost identical. 534 
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 535 
Figure 2. Relationship between FCoV and GAPDH Ct values for non-effusive FIP 536 
samples where FCoV was detected. A moderate positive correlation (r = 0.72, P < 0.01) 537 
was detected between Ct values of the ‘test’ gene, FCoV, and the reference host control 538 
gene, GAPDH. Thus, broadly, the lower level of host RNA detected, the lower level of 539 
FCoV detected. 540 
 541 
